Skip to content

News

10th December 2024

Merakris Therapeutics Announces Open Enrollment for Phase II Clinical Trial of Subcutaneous Injection Drug for the Treatment of VLU

1st October 2024

Merakris Therapeutics Introduces Dermacyte® AC Matrix: A Lyophilized Amnion Chorion Allograft

5th September 2024

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid

9th May 2024

Jonathan Berlent Joins Merakris as SVP, Head of Strategy and Operations

12th March 2024

Favorable Results From Dermacyte® Matrix Research Study Published in March Issue of Journal of Wound Care

Top